Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.

IF 3.3 Q2 GASTROENTEROLOGY & HEPATOLOGY

BMJ Open Gastroenterology Pub Date : 2025-01-23 DOI:10.1136/bmjgast-2024-001657

Aidana Mustafa, Salima Davlidova, Syed Hani Abidi, Dinara Begimbetova, Robert Heimer, Sten H Vermund, Syed Ali

{"title":"Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries.","authors":"Aidana Mustafa, Salima Davlidova, Syed Hani Abidi, Dinara Begimbetova, Robert Heimer, Sten H Vermund, Syed Ali","doi":"10.1136/bmjgast-2024-001657","DOIUrl":null,"url":null,"abstract":"Objective: The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. This study's objective was to observe the prevalence of HCV genotypes and RAS within the Former Soviet Union (FSU) countries.Methods: We analysed 60 NS3, 313 NS5A and 1119 NS5B sequences of HCV deposited in open-access databases from 11 FSU countries for the prevalence of genotypes and the presence of RAS using the Geno2Pheno software.Results: The following NS3 RASs were revealed through our analyses: 156P/S/T, 168del, 80K, 55A and 174S. The most prevalent NS5A RAS was 30K (12.69%) in genotype 3a, associated with resistance to daclatasvir, elbasvir and ledipasvir, followed by 62S (8.96% in genotype 3a), linked with resistance to daclatasvir, and 93H (3.95% and 6.72% in genotypes 1b and 3a, respectively), conferring resistance to daclatasvir, ombitasvir, elbasvir, ledipasvir and velpatasvir. The NS5B RASs found in this study were 451S and 556G, associated with resistance to dasabuvir.Conclusion: The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries.","PeriodicalId":9235,"journal":{"name":"BMJ Open Gastroenterology","volume":"12 1","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758705/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjgast-2024-001657","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The emergence of resistance-associated substitutions (RASs) poses a significant challenge to the effective treatment of hepatitis C virus (HCV) infection using direct-acting antivirals. This study's objective was to observe the prevalence of HCV genotypes and RAS within the Former Soviet Union (FSU) countries.

Methods: We analysed 60 NS3, 313 NS5A and 1119 NS5B sequences of HCV deposited in open-access databases from 11 FSU countries for the prevalence of genotypes and the presence of RAS using the Geno2Pheno software.

Results: The following NS3 RASs were revealed through our analyses: 156P/S/T, 168del, 80K, 55A and 174S. The most prevalent NS5A RAS was 30K (12.69%) in genotype 3a, associated with resistance to daclatasvir, elbasvir and ledipasvir, followed by 62S (8.96% in genotype 3a), linked with resistance to daclatasvir, and 93H (3.95% and 6.72% in genotypes 1b and 3a, respectively), conferring resistance to daclatasvir, ombitasvir, elbasvir, ledipasvir and velpatasvir. The NS5B RASs found in this study were 451S and 556G, associated with resistance to dasabuvir.

Conclusion: The high prevalence of HCV genotypes 1b and 3a in the FSU region and the presence of specific RASs should be considered when determining the most effective treatment regimen for HCV-infected individuals in the FSU countries.

查看原文本刊更多论文

前苏联国家丙型肝炎病毒耐药相关替代（RAS）的流行

目的：耐药性相关替代药物（RASs）的出现对使用直接作用抗病毒药物有效治疗丙型肝炎病毒（HCV）感染提出了重大挑战。本研究的目的是观察前苏联（FSU）国家HCV基因型和RAS的流行情况。方法：采用gen2pheno软件分析来自11个FSU国家的开放获取数据库中保存的60个NS3、313个NS5A和1119个NS5B序列的HCV基因型患病率和RAS的存在。结果：我们通过分析发现了以下NS3 ras: 156P/S/T、168del、80K、55A和174S。基因型3a中最常见的NS5A RAS为30K(12.69%)，与daclatasvir、elbasvir和ledipasvir耐药有关，其次是62S（基因型3a为8.96%），与daclatasvir耐药有关，其次是93H（基因型1b和3a分别为3.95%和6.72%），与daclatasvir、ombitasvir、elbasvir、ledipasvir和velpatasvir耐药有关。本研究中发现的NS5B ras为451S和556G，与达沙布韦耐药相关。结论：FSU地区HCV基因型1b和3a的高流行率以及特异性RASs的存在应在确定FSU国家HCV感染者最有效的治疗方案时加以考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ Open Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

5.90

自引率

3.20%

发文量

审稿时长

2 weeks

期刊介绍： BMJ Open Gastroenterology is an online-only, peer-reviewed, open access gastroenterology journal, dedicated to publishing high-quality medical research from all disciplines and therapeutic areas of gastroenterology. It is the open access companion journal of Gut and is co-owned by the British Society of Gastroenterology. The journal publishes all research study types, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Publishing procedures are built around continuous publication, publishing research online as soon as the article is ready.